CROs and trial design

Shire links with US hospital for rare disease research
Shire links with US hospital for rare disease research Willwork with Cincinnati Children's Hospital Medical Centre novel therapies
FDA awards $19m in rare disease grants
FDA awards $19m in rare disease grants US regulator supports 15 orphan drug projects
The moving parts of orphan drug development
The moving parts of orphan drug development Tackling rare diseases requires high levels of cooperation, regulatory support and a determination to succeed
Shire boosts rare disease portfolio with $260m Lumena deal
Shire boosts rare disease portfolio with $260m Lumena deal Acquisition of US company will bring two mid-stage candidates for rare liver diseases
Amgen cholesterol antibody shines in rare disease trial
Amgen cholesterol antibody shines in rare disease trial Evolocumab passes late-stage study
WCCT Global talks up orphan drug benefits of new service
WCCT Global talks up orphan drug benefits of new service CRO's In-Site programme will harness digital technology for patient recruitment
Sanofi strikes $700m rare diseases deal
Sanofi strikes $700m rare diseases deal Company's Genzyme division will obtain significant rights to Alnylam’s pipeline of orphan drugs
Novartis myeloma drug clears phase III trial
Novartis myeloma drug clears phase III trial Panobinostat on course to be first in new class of treatment for bone marrow cancer
Shire snaps up Viropharma to build $2bn rare disease unit
Shire snaps up Viropharma to build $2bn rare disease unit Gains access to Cinryze in expensive but 'strategically sound' deal
GSK wins anthrax contract from US government
GSK wins anthrax contract from US government Signs $196m deal for its monoclonal anti-toxin raxibacumab
Chiesi acquires Zymenex and mulls new rare disease unit
Chiesi acquires Zymenex and mulls new rare disease unit Deal adds late-stage orphan drug to Italian pharma company's pipeline
Shire extends rare genetic disease alliance
Agrees option with Santaris to nominate additional discovery targets
EC sets up expert group on rare diseases
EC sets up expert group on rare diseases Will revamp EUCERD to better handle development of orphan medicines
Boehringer: clinical trial set-up poses challenge in rare diseases
Boehringer: clinical trial set-up poses challenge in rare diseases Says more support needed in regulatory process for orphan drugs
Rare diseases among initial priorities of UK DNA mapping body
Rare diseases among initial priorities of UK DNA mapping body Genomics England will also help advance research into cancer and infectious diseases
Healthcare at Home and QED partner on orphan diseases
OrphanReach alliance will see companies provide product lifecycle services
Roche and Isis in $392m deal to research drugs for brain disorder
Roche and Isis in $392m deal to research drugs for brain disorder Will develop antisense drugs for Huntington's disease
Santhera's Raxone turned down for rare eye condition
Santhera's Raxone turned down for rare eye condition EMA concerned about drug's ability to improve eyesight
PatientsLikeMe takes aim at one of world's rarest diseases
PatientsLikeMe takes aim at one of world's rarest diseases Creates open registry and community for alkaptonuria patients
Pfizer acquires spinal muscular atrophy research programme
Pfizer acquires spinal muscular atrophy research programme Gains rights to drug candidate RG3039 in deal with Repligen that could be worth up to $70m

1